Related Experiment Video

Updated: Jun 10, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells

Akinori Sato1, Takako Asano, Akio Horiguchi

  • 1Department of Urology, National Defense Medical College, Tokorozawa, Saitama, Japan. zenpaku@ndmc.ac.jp

Urology
|July 16, 2010
PubMed
Abstract

Insights

Combining suberoylanilide hydroxamic acid (SAHA) and ritonavir effectively inhibits renal cancer cell proliferation by inducing apoptosis. This combination therapy shows promise for treating kidney cancer with minimal impact on normal kidney cells.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Kidney cancer remains a significant health concern with limited treatment options.
  • Histone deacetylase (HDAC) inhibitors and protease inhibitors are emerging as potential therapeutic agents.

Purpose of the Study:

  • To evaluate the synergistic effect of SAHA and ritonavir on renal cancer cells.
  • To investigate the underlying molecular mechanisms of this combination therapy.

Main Methods:

  • Renal cancer cell lines and normal renal cells were treated with varying concentrations of SAHA and ritonavir.
  • Cell viability, proliferation, cell cycle, and apoptosis markers were assessed.
  • Protein expression levels of key molecules were analyzed via Western blot.

Main Results:

  • SAHA alone induced histone acetylation and inhibited cell growth.
  • The combination of SAHA and ritonavir significantly inhibited cancer cell proliferation and induced apoptosis.
  • This combination demonstrated minimal toxicity to normal renal proximal tubule epithelial cells.
  • The treatment led to decreased expression of X-linked inhibitor of apoptosis and survivin, and increased active caspase 3.

Conclusions:

  • Combination therapy with SAHA and ritonavir is a potent strategy for inhibiting renal cancer cell proliferation.
  • The observed effects are likely mediated by the inhibition of HDAC function and expression, leading to apoptosis.
  • This regimen holds potential as a novel treatment for renal cancer.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...